隐球菌病的诊治进展

中国真菌学杂志　 2011, Vol. 6 　Issue (3): 186-189.

隐球菌病的诊治进展

李平, 温海

第二军医大学附属长征医院皮肤科, 上海, 200003

收稿日期:2010-11-28 出版日期:2011-06-28 发布日期:2011-06-28
通讯作者: 温海,E-mail:wenhai98@sohu.com E-mail:wenhai98@sohu.com
作者简介:李平,男(汉族),博士研究生在读,主治医师.E-mail:lympin@tom.com

Received:2010-11-28 Online:2011-06-28 Published:2011-06-28

摘要/Abstract

摘要： 隐球菌通常感染免疫功能低下的患者,荚膜多糖是其主要的致病因子,隐球菌主要通过肺进入机体从而引起肺隐球菌病,但因其嗜神经的特性,中枢神经系统也是隐球菌的主要靶器官。隐球菌感染的主要危险因素包括H IV感染和器官移植。由于感染部位的不同和患者的免疫功能的差异,其临床症状也多种多样,轻者无症状,重者危及生命。治疗方案主要由患者的免疫状态和病情的严重程度决定,主要包括多烯类和咪唑类抗真菌药物的治疗。即使经过抗真菌治疗,H IV患者隐球菌病的病死率仍较高,而CME(隐球菌性脑膜炎/脑膜脑炎)患者的临床治疗失败率之高让人难以接受。现介绍近年来隐球菌病在诊断和治疗方面的进展,并对未来治疗的发展趋势作简要的评价。

中图分类号:

R379.5

李平, 温海. 隐球菌病的诊治进展[J]. 中国真菌学杂志, 2011, 6(3): 186-189.

参考文献

[1] Ritter M,Goldman DL.Pharmacotherapy of cryptococcosis[J].Expert Opin Pharmacother,2009,10(15):2433-2443.
[2] Lortholary O,Poizat G,Zeller V,et al.Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy[J].AIDS,2006,20(17):2183-2191.
[3] Lindell RM,Hartman TE,Nadrous HF,et al.Pulmonary cryptococcosis:CT findings in immunocompetent 19 patients[J].Radiology,2005,236(1):326-331.
[4] Chayakulkeeree M,Perfect JR.Cryptococcesis[J].Infect Dis Clin N Am,2006,20(3):507-544.
[5] Sato Y,Osabe S,Kuno H,et al.Rapid diagnosis of cryptococcal meningitis by microscopic examination of centrifuged cerebrospinal fluid sediment[J].J Neurol Sci,1999,164(1):72-75.
[6] Feldmesser M,Harris C,Reichberg S,et al.Serum cryptococcal antigen in patients with AIDS[J].Clin Infect Dis,1996,23(4):827-830.
[7] Sidrim JJ,Costa AK,Cordeiro RA,et al.Molecular methods for the diagnosis and characterization of Cryptococcus:a review[J].Can J Microbiol,2010,56(6):445-458.
[8] Alexander BD,Perfect JR,Daly JS,et al.Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant[J].Transplantation,2008,86(6):791-796.
[9] Bandettini R,Castagnola E,Calvillo M,et al.Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant[J].J Chemother,2009,21(1):108-109.
[10] Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease[J].Clin Infect Dis,2000,30(4):710-718.
[11] 《中国真菌学杂志》编辑委员会.隐球菌感染诊治专家共识[J].中国真菌学杂志,2010,5(2):65-68.
[12] Perfect JR,Dismukes WE,Dromer F,et al.Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of America[J].Clin In fect Dis,2010,50(3):291-322.
[13] Larsen RA,Leal MA,Chan LS.Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS.A randomized trial[J].Ann Intern Med,1990,113(3):183-187.
[14] Longley N,Muzoora C,Taseera K,et al.Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda[J].Clin Infect Dis,2008,47(12):1556-1561.
[15] Newton PN,Thai LH,Tip NQ,et al.A randomized,doubleblind,placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis[J].Clin Infect Dis,2002,35(6):769-772.
[16] Baddley JW,Perfect JR,Oster RA,et al.Pulmonary cryptococcosis in patients without HIV infection:factors associated with disseminated disease[J].Eur J Clin Microbiol Infect Dis,2008,27(10):937-943.
[17] 刘明,姜格宁.肺隐球菌病的外科治疗[J].中华结核呼吸杂志,2006,29(5):307-309.
[18] Revenga F,Paricio JF,Merino FJ.Primary cutaneous eryptococcosis in an immunocompetent host:case report and review of the literature[J].Dermatology,2002,204(2):145-149.
[19] Dromer F,Charreire J.Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody:study during murine cryptococcosis and mechanisms of action[J].J In-fect Dis,1991,163(5):1114-1120.
[20] Larsen RA,Pappas PG;,Perfect J,et al.Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis[J].Antimicrob Agents Chemother,2005,49(3):952-958.
[21] Siddiqui AA,Brouwer AE,Wuthiekanun V,et al.IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis[J].J Immunal,2005,174(3):1746-1750.